Primary Image

generic image

Clinical Trial

A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2a Study of NVG-291 in Spinal Cord Injury Subjects

IRB Protocol Number STU00219033

Contact

nvg@sralab.org

Objective

This study is examining how the study drug, NVG-291, affects nerve connections in the spinal cord and whether it is safe and tolerable to use.

Volunteers in this study will:

  • Participate in study visits over 16 weeks.
  • Visits will take place at the Shirley Ryan 外网天堂.

Visit involves:  

  • Non-invasive stimulation of the brain and spinal cord and startle acoustic stimuli.
  • Upper and lower limb training
  • Answer questionnaire
  • Physiological and physical assessments
  • Receiving daily injections of NVG-291 or placebo.

Who Can Participate

Participants with a spinal cord injury who are:

  • Between 18-75 years of age 
  • Sustained a spinal cord injury at C1-C7 (1 -10 years post injury) 
  • In good physical health 
  • Proficiency in English

Compensation

Receive compensation

Apply for this Trial

Your information will not be published.

All fields are required.

Featured Quote

More Studies

Share Your Experience Flying with a Physical Disability

Researchers at Shirley Ryan 外网天堂, Northwestern University, and Indiana University are conducting two research studies to understand the challenges people with physical disabilities face during air travel, as well as the factors that could improve their travel experience and help airlines and airports become more inclusive and accessible.

read more
view all

Latest Updates

view all